Rep. Alexandria Ocasio-Cortez confronted a CEO Thursday for pricing a drug designed to reduce the risk of HIV transmission at $8 in Australia but over $1,500 in the U.S.
“You’re the CEO of Gilead. Is it true that Gilead made $3 billion in profits from Truvada in 2018?” Ocasio-Cortez asked Gilead CEO Daniel O’Day.
“$3 billion in revenue,” he clarified.
“The current list price is $2,000 a month in the United States, correct?” she asked, referring to Truvada.
“It’s $1,780 in the United States,” O’Day responded.
“Why is it $8 in Australia?” Ocasio-Cortez countered.
“Truvada still has patent protection in the United States and in the rest of the world it is generic,” O’Day explained, adding, “It will be generically available in the United States as of September 2020.”
Still, Ocasio-Cortez stated “There’s no reason this should be $2,000 a month. People are dying because of it and there’s no enforceable reason for it.”
Read more at The Hill.